TMRW Robotic Process Automation Platform Goes Live at San Diego Fertility Center
NEW YORK:
TMRW, the creator of the first Robotic Process Automation (RPA) platform specifically designed for in vitro fertilization (IVF), announced today the company has commenced a multi-site study to test its platform in a live clinical environment.
The study has been launched in partnership with the San Diego Fertility Center (SDFC) in California, Vios Fertility Institute (VIOS) in Chicago, Illinois and Reproductive Medicine Associates of New York (RMA of New York). The study will test the platform in real-time — measuring improvements achieved through automation and allowing for instant iteration of platform technology.
A total of six leading clinics in major markets around the country are expected to participate in the study in coming weeks.
We are thrilled to see the TMRW platform tested in live clinical environments and are grateful for the cooperation and partnership of the SDFC, Vios Fertility Institute and RMA of New York. As access to IVF therapies grows globally, it's absolutely imperative that embryo preservation evolves past the 40-year-old technology used in fertility medicine, said Dr. Jeff Port, TMRW's co-founder and Chief Medical Officer. We anticipate 200-300 million IVF births this century, of which the majority will be associated with cells that were once frozen. TMRW's automated cryo-preservation process performs up to 17,000 'health checks' daily to establish the perfect storage environment. Our platform is customized to meet this surging demand while reducing risk and providing peace of mind that both physicians and their patients justifiably seek.
Advancements in embryo vitrification and IVF therapies have significantly improved patient outcomes, explains Dr. Angeline Beltsos, CEO and Chief Medical Officer of Vios Fertility Institute. As the need for embryo, egg and sperm storage grows, TMRW's platform will streamline workflow, cryo-preservation and the security we offer our patients. As more people turn to IVF to have a family, we need innovative partners like TMRW to accommodate the growing demand of tissue storage and provide transparency. We look forward to getting started with this cutting edge technology.
TMRW's state-of-the-art platform was designed to mitigate human error and monitor the environment of frozen embryos and eggs around the clock. The platform replaces current analog IVF cryo-preservation and tissue management system, by implementing automated cryo-management and RFID-enabled digital chain of custody for embryos and gametes.
Advances in technology have helped countless patients build their families. Genetic testing and freezing of embryos is now routine, and success rates are higher than ever, said Dr. Alan Copperman, Medical Director of RMA of New York. Innovations in automation, cryostorage and monitoring will be essential to meet the needs of our current and future patients.
Our patients come from across the world seeking the absolute best standard of care and they expect leadership on issues of safety, transparency and technology, said Dr. Michael Kettel, Senior Physician at the San Diego Fertility Center. We believe the benefits offered by the TMRW RPA will put many patients' minds at ease and ultimately improve their outcomes. We have no higher priority.
A total of six leading clinics in major markets around the country are expected to participate in the study in coming weeks.
We are thrilled to see the TMRW platform tested in live clinical environments and are grateful for the cooperation and partnership of the SDFC, Vios Fertility Institute and RMA of New York. As access to IVF therapies grows globally, it's absolutely imperative that embryo preservation evolves past the 40-year-old technology used in fertility medicine, said Dr. Jeff Port, TMRW's co-founder and Chief Medical Officer. We anticipate 200-300 million IVF births this century, of which the majority will be associated with cells that were once frozen. TMRW's automated cryo-preservation process performs up to 17,000 'health checks' daily to establish the perfect storage environment. Our platform is customized to meet this surging demand while reducing risk and providing peace of mind that both physicians and their patients justifiably seek.
Advancements in embryo vitrification and IVF therapies have significantly improved patient outcomes, explains Dr. Angeline Beltsos, CEO and Chief Medical Officer of Vios Fertility Institute. As the need for embryo, egg and sperm storage grows, TMRW's platform will streamline workflow, cryo-preservation and the security we offer our patients. As more people turn to IVF to have a family, we need innovative partners like TMRW to accommodate the growing demand of tissue storage and provide transparency. We look forward to getting started with this cutting edge technology.
TMRW's state-of-the-art platform was designed to mitigate human error and monitor the environment of frozen embryos and eggs around the clock. The platform replaces current analog IVF cryo-preservation and tissue management system, by implementing automated cryo-management and RFID-enabled digital chain of custody for embryos and gametes.
Advances in technology have helped countless patients build their families. Genetic testing and freezing of embryos is now routine, and success rates are higher than ever, said Dr. Alan Copperman, Medical Director of RMA of New York. Innovations in automation, cryostorage and monitoring will be essential to meet the needs of our current and future patients.
Our patients come from across the world seeking the absolute best standard of care and they expect leadership on issues of safety, transparency and technology, said Dr. Michael Kettel, Senior Physician at the San Diego Fertility Center. We believe the benefits offered by the TMRW RPA will put many patients' minds at ease and ultimately improve their outcomes. We have no higher priority.